SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Reduce Stake in Pliant Therapeutics to 0.2%

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, indicating a reduction in their beneficial ownership of Pliant Therapeutics Inc. common stock to 0.2% of the outstanding class.

Summary

• FMR LLC and Abigail P. Johnson, through an amended Schedule 13G filing, reported their beneficial ownership in Pliant Therapeutics Inc. (PLRX) common stock.
• As of February 28, 2025, the aggregate amount beneficially owned by FMR LLC and Abigail P. Johnson is 131,993.45 shares.
• This represents 0.2% of the total outstanding common stock of Pliant Therapeutics Inc.
• FMR LLC holds sole voting power over 120,992.00 shares and sole dispositive power over 131,993.45 shares.
• Abigail P. Johnson holds sole dispositive power over 131,993.45 shares, with no sole or shared voting power.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• This is Amendment No. 7 to their Schedule 13G filing, implying a reduction from a previously reported stake that was above the 5% threshold.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the implied reduction in a significant institutional investor's stake, which could be interpreted as a loss of confidence or a portfolio reallocation away from the company.

Negatives

• The reduction in beneficial ownership by a significant institutional investor like FMR LLC, bringing their stake below the 5% reporting threshold, could be perceived as a negative signal by the market, indicating a decreased conviction or reallocation of assets.

Risks

• The filing itself does not detail specific risks related to Pliant Therapeutics Inc.'s operations or financial health. It primarily concerns the beneficial ownership stake of the reporting entities.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, which is a standard disclaimer for Schedule 13G filings and mitigates control-related risks from this specific investor.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Pliant Therapeutics Inc.'s future performance or strategic direction.

Management Comments

• Stephanie J. Brown, Duly authorized under Power of Attorney, signed on behalf of FMR LLC and Abigail P. Johnson, certifying that the information set forth in the statement is true, complete, and correct.

Industry Context

This filing reflects a change in an institutional investor's stake in a biotechnology company. Such changes are common in the highly dynamic biotech sector, where investment firms frequently adjust their portfolios based on clinical trial results, regulatory milestones, and market valuations. This specific filing does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: May view the reduction in institutional ownership as a negative signal, potentially impacting investor confidence, though the direct impact on share price depends on the market's interpretation and the size of the previous stake.
• Employees, Customers, Suppliers, Creditors: Unlikely to be directly impacted by this beneficial ownership filing, as it does not relate to the company's operations, financial health, or strategic direction.

Key Dates

Keywords

Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, FMR LLC, Abigail P. Johnson, Pliant Therapeutics Inc., PLRX, Common Stock, Ownership Update